50 Successful Marketing Applications
Since 1988
50+ Successful
Marketing Applications
A History of Impact in Drug Development
New webinar series presents:
Expedited Development:
Qualifying for
Breakthrough Therapy or Fast Track Designations
Did you miss it?
previous arrow
next arrow
Slider

Service Solutions

Cato Research, Your Reliable Partner

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients since 1988. Through highly qualified and experienced personnel located in offices across North America, Europe, Israel, and South Africa, supported by strategic alliances with selected regional CROs, CATO offers tried-and-trusted international coverage.

CATO has the advantage of integrated regulatory, clinical, and scientific expertise. Our highly talented and experienced international team offers services from preclinical through IND (or equivalent), clinical development, and marketing approval to Phase 4 postmarketing research. Our track record includes successes across many different health products, including drugs, biologics, vaccines, cell therapies (including stem cells), nutriceuticals, medical foods, devices, and diagnostics. In terms of diseases and indications, CATO has been involved in a wide variety of projects with a dominant focus in oncology, neurology/CNS, and rare and orphan drug indications. This experience includes leadership of, and involvement in some of the most challenging and innovative products.

Therapeutic Expertise

What our Sponsors say about us...

“…Thanks to all of you!

"...Thanks to all of you!  You guys are terrific!  It's a real pleasure to work with you.  Thanks to all the efforts and professional work.  Looking forward for the next phase on this project!
Please find attached the APPROVAL letter for Product.  Please share in our excitement as you have been partners in this adventure!"

Global U.S. Biotechnology Company

2017-11-21T21:08:17-04:00

Global U.S. Biotechnology Company

"...Thanks to all of you!  You guys are terrific!  It's a real pleasure to work with you.  Thanks to all the efforts and professional work.  Looking forward for the next phase on this project! Please find attached the APPROVAL letter for Product.  Please share in our excitement as you have been partners in this adventure!"

“Dear Cato team,

Thank you so much for all your hard work which has resulted in our NDA being submitted one day earlier than our already extremely tight timeline.


All our partners were very surprised when we set such an ambitious timeline in April when we changed from a paper CR to an eCTD, and many have said they did not think we would make it.  But with your team spirit and hard work the impossible has been made possible."

-Specialty Pharmaceutical Company

2017-11-21T21:16:33-04:00

-Specialty Pharmaceutical Company

Thank you so much for all your hard work which has resulted in our NDA being submitted one day earlier than our already extremely tight timeline. All our partners were very surprised when we set such an ambitious timeline in April when we changed from a paper CR to an eCTD, and many have said they did not think we would make it.  But with your team spirit and hard work the impossible has been made possible."

Upcoming Events

No event found!
Load More

Cato Research Blog

  • Complicated Drug Product? FDA Releases New Draft...
    by Cato Research on July 23, 2019 at 8:27 pm

    Complicated Drug Product? FDA Releases New Draft Guidance on Instructions for Use to Help Sponsors Communicate Proper Use to the Patient By Dieanira Erudaitius, Ph.D, Scientist at Cato Research This month, July 2019, the United States Food and Drug Administration (FDA) released a new draft guidance […]

  • New FDA Guidance’s For May 2019
    by Cato Research on June 14, 2019 at 2:32 pm

    Special Interest Guidances/Information Date Posted Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff – Final Guidance 30 May 2019 Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;: Guidance for […]

Twitter @CatoResearch

LinkedIn Cato Research

Facebook @catoresearch

Searching for something else?